Search
for
Sort by
Research 30 of 116
- Successful treatment of alopecia universalis with abrocitinib: a case report
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
- A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
- Treatment of Lichen Planopilaris With Abrocitinib
- Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review
- Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
- 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
- 63407 A Descriptive Analysis of Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Alopecia Areata in the Abrocitinib JADE Clinical Program
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- A case of dupilumab-induced psoriatic alopecia
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Turning JAK STATic, a peek into the future of dermatology therapeutics